Closed
National Generic Pharmaceuticals – Project Revive
NHS England
- Value
- £1.20
- Published
- 20 Aug 2026
- Deadline
- 25 Sept 2026
- Procedure
- Not stated
- Category
- 33600000 — Pharmaceutical products
- Location
- London, UKI45, SE1 8UG, United Kingdom
- Notice reference
- 079388-2026
Requirements summary
NHS England is running preliminary market engagement for a National Generic Pharmaceuticals framework called Project Revive, covering three regional groups (DCE/DSW, DLS/DNE, DLN/DNW). The programme aims to reactivate dormant MHRA-approved marketing authorisations and find new supply routes for critical generic medicines, focused on secondary care supply resilience. The contract period is 1 April 2027 to 31 January 2029 (22 months), with an option to extend to a maximum of 48 months, and specific products will be set out in the Invitation to Offer (ITO).
Key requirements
- Supply of generic pharmaceuticals for NHS secondary care under a framework agreement
- Reactivation of dormant or not-marketed MHRA-approved marketing authorisations for critical products
- Coverage of three regional groups: DCE/DSW, DLS/DNE and DLN/DNW
- Contract period from 1 April 2027 to 31 January 2029 (22 months), extendable to a maximum of 48 months
- Engagement with preliminary market engagement by 25 September 2026; tender issue moved to 1 October 2026
- Specific product list to be provided in the ITO
Similar open notices
- NHS National Framework Agreement for Macitentan & Cladribine TabletsNHS England
- NHS National Framework Agreement for Macitentan & Cladribine TabletsNHS England
- Injection Equipment ParaphernaliaThe Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
- Framework for the Provision of Dose Banded Products & Patient Specific Chemotherapy ServicesUniversity Hospitals of Derby and Burton NHS Foundation Trust
- NEYPPC Pharmacy - Unlicensed Imported Medicines (wave 2)Leeds Teaching Hospitals NHS Trust